Alembic Pharmaceuticals Ltd. - Research Center
533573 APLLTD Group (A) BSE data
Add to watchlist
| Results |
Quarterly
|
| Statement | |
| More |
Quarterly results in brief
(Rs crore)
| Jun' 21 | Mar' 21 | Dec' 20 | Sep' 20 | Jun' 20 | |
|---|---|---|---|---|---|
| Sales | 1,269.69 | 1,157.24 | 1,235.77 | 1,400.01 | 1,258.43 |
| Operating profit | 276.97 | 320.99 | 371.75 | 456.15 | 423.35 |
| Interest | 2.03 | 2.14 | 2.21 | 2.33 | 6.09 |
| Gross profit | 276.68 | 322.88 | 372.25 | 456.66 | 417.42 |
| EPS (Rs) | 9.80 | 11.76 | 14.11 | 17.72 | 16.90 |
Quarterly
results in details
| Jun' 21 | Mar' 21 | Dec' 20 | Sep' 20 | Jun' 20 | |
|---|---|---|---|---|---|
| Other income | 1.74 | 4.03 | 2.71 | 2.84 | 0.16 |
| Stock adjustment | -17.58 | -39.73 | -91.43 | -63.82 | 37.85 |
| Raw material | 287.02 | 270.57 | 325.55 | 322.66 | 256.93 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 261.59 | 212.01 | 236.53 | 250.36 | 249.37 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 461.69 | 393.40 | 393.37 | 434.66 | 290.93 |
| Provisions made | - | - | - | - | - |
| Depreciation | 43.49 | 41.84 | 38.21 | 36.71 | 35.84 |
| Taxation | 40.50 | 49.93 | 56.69 | 71.65 | 62.94 |
| Net profit / loss | 192.69 | 231.11 | 277.35 | 348.30 | 318.64 |
| Extra ordinary item | - | - | - | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 39.31 | 39.31 | 39.31 | 39.31 | 37.70 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 21.81 | 27.74 | 30.08 | 32.58 | 33.64 |
| GPM (%) | 21.76 | 27.80 | 30.06 | 32.55 | 33.17 |
| NPM (%) | 15.16 | 19.90 | 22.39 | 24.83 | 25.32 |
Mutual Fund Selector
Find the fund that is right for you
© 2021 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis